Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum.
Richard M
RM
Ransohoff
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016543:Central Nervous System Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D003951:Diagnostic Errors; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab